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CHEMOKINES, CYTOKINES, AND INTERLEUKINS
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Angiogenesis plays a key role in various
physiologic and pathologic conditions,
including tumor growth. Drm/gremlin, a
member the Dan family of bone morpho-
genic protein (BMP) antagonists, is com-
monly thought to affect different pro-
cesses during growth, differentiation, and
development by heterodimerizing vari-
ous BMPs. Here, we identify Drm/gremlin
as a novel proangiogenic factor expressed
by endothelium. Indeed, Drm/gremlin was
purified to homogeneity from the condi-
tioned medium of transformed endothe-
lial cells using an endothelial-cell sprout-
ing assay to follow protein isolation.
Accordingly, recombinant Drm/gremlin
stimulates endothelial-cell migration and
invasion in fibrin and collagen gels, binds
with high affinity to various endothelial
cell types, and triggers tyrosine phosphor-
ylation of intracellular signaling proteins.
Also, Drm/gremlin induces neovascular-
ization in the chick embryo chorioallan-
toic membrane. BMP4 does not affect
Drm/gremlin interaction with endothe-
lium, and both molecules exert a proan-
giogenic activity in vitro and in vivo when
administered alone or in combination.
Finally, Drm/gremlin is produced by the
stroma of human tumor xenografts in
nude mice, and it is highly expressed in
endothelial cells of human lung tumor
vasculature when compared with non-
neoplastic lung. Our observations point
to a novel, previously unrecognized ca-
pacity of Drm/gremlin to interact directly
with target endothelial cells and to modu-
late angiogenesis. (Blood. 2007;109:
1834-1840)
© 2007 by The American Society of Hematology
Introduction
Gremlin, also known as Drm (Down-regulated by v-mos), belongs
to the Dan family of cysteine knot-secreted proteins.1,2 Drm/
gremlin exerts a potent bone morphogenic protein (BMP) antago-
nist activity by binding BMP2, BMP4, and BMP7 and preventing
their interaction with cell-surface receptors.3 This capacity is
thought to be responsible for the pattern-inducing activity of
Drm/gremlin during embryonic development4 and to play a role in
human diseases.5 However, intracellular, BMP-independent mecha-
nism(s) of action6 may mediate the ability of Drm/gremlin to
suppress transformation and tumorigenesis under certain experimen-
tal conditions.7 Also, Drm/gremlin interacts with Slit proteins and
acts as a negative regulator of monocyte chemotaxis, thus suggest-
ing a role for this protein in inflammation and immunity.8 Taken
together these observations indicate that Drm/gremlin may exert
multiple functions in different physiopathologic conditions via
BMP-dependent and BMP-independent mechanisms of action.1-5
Nevertheless, the possibility that Drm/gremlin may exert a direct
effect on target cells has never been explored.
Angiogenesis, the process of new blood vessel formation from
preexisting ones, plays a key role in various physiologic and
pathologic conditions, including inflammation and tumor growth.9
The local, continuous release of angiogenic growth factors and/or
alterations of the production of natural angiogenic inhibitors10 are
responsible for the uncontrolled endothelial-cell proliferation that
takes place during tumor neovascularization and in angiogenesis-
dependent diseases.11 Numerous inducers of angiogenesis have
been identified, including members of the vascular endothelial
growth factor (VEGF)12,13 and of the fibroblast growth factor
(FGF) families.14 These angiogenic growth factors induce a
complex “proangiogenic phenotype” in endothelial cells that
recapitulates several aspects of the in vivo angiogenesis process
(summarized in Javerzat et al15).
To elucidate the molecular determinants of endothelial-cell
activation during angiogenesis, we originated a stable mouse aortic
endothelial (MAE) cell line transfected with a human FGF2 cDNA
(FGF2-T-MAE cells).16,17 Transfectants are characterized by the
overexpression of numerous genes implicated in the modulation
of cell growth, differentiation, cell adhesion, and stress/
survival.18 FGF2-T-MAE cells are angiogenic and cause the
formation of opportunistic vascular lesions by recruiting endo-
thelial cells of the host.16,19 Accordingly, FGF2-T-MAE cells
release an endothelial-cell motogen that appears to be distinct
from other well-characterized angiogenic growth factors, includ-
ing FGF2 and VEGF.19
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Here, we describe the purification of this factor from the
conditioned medium (CM) of FGF2-T-MAE cells and its identifica-
tion as the Drm/gremlin protein. Our data demonstrate for the first
time that Drm/gremlin plays a BMP-independent role in the
angiogenic process by binding the endothelial cell surface, thus
activating intracellular signaling and cell motility. Accordingly,
Drm/gremlin induces new vessel growth in the chick embryo
chorioallantoic membrane. Also, the expression of Drm/gremlin in
the endothelium of human lung tumor specimens points to a role
for this protein in blood vessel development in human cancers.
Materials and methods
Cell cultures
Immortalized Balb/c MAE cells were obtained from R. Auerbach (Univer-
sity of Wisconsin, Madison) and grown in Dulbecco modified minimal
essential medium (DMEM; Gibco Life Technologies, Rockville, MD)
combined with 10% FCS (Gibco Life Technologies). FGF2-T-MAE cells
were grown in DMEM supplemented with 4 mM glutamine (Gibco Life
Technologies) and 10% FCS. Bovine aortic endothelial (BAE) cells and
normal subcutaneous microvascular endothelial (SIE) cells20 (both pro-
vided by A. Vecchi, Istituto Mario Negri, Milan, Italy) were cultured in
DMEM supplemented with 10% heat-inactivated donor calf serum. Human
umbilical vein endothelial (HUVE) cells were cultured in EGM-2 medium
(Clonetics, Palo Alto, CA).
Drm/gremlin purification
Conditioned medium (CM) was prepared by incubating confluent FGF2-T-
MAE cell cultures grown in 10-cm dishes with 8 mL serum-free DMEM for
2 to 3 days. CM (21 L) was precipitated with 70% of ammonium sulfate.
Then, the protein precipitate was dissolved in 40 mL of 25 mM MES/NaOH
(pH 6.5) plus 1.0 mM PMSF and dialyzed against the same buffer. The
dialyzed protein fraction (2 mg/mL) was applied onto a 80-mL Sp-
Sepharose Fast Flow column (Amersham Bioscience, Uppsala, Sweden)
pre-equilibrated with 50 mM MES/NaOH (pH 6.5). The column was
extensively washed with 50 mM MES/NaOH (pH 7.5) and eluted at a flow
rate of 30 mL/hour with a linear 0 to 1.0 M NaCl gradient at 4°C. The eluate
was collected in 10-mL fractions, and aliquots from each fraction were
assayed for their ability to stimulate MAE-cell sprouting in 3-dimensional
fibrin gel.19 The biologically active fractions eluted at 0.8 to 0.9 M NaCl
(see Figure 1B) were pooled together (10 mg total protein) and concentrated
10 times with a 30-kDa cutoff ultrafiltration system (Amicon, Bedford,
MA). Proteins were then loaded onto a 10-mL heparin-Sepharose column
equilibrated in 10 mM Mes/NaOH (pH 7.0) and eluted with a linear 0 to
1.0 M NaCl gradient at 4°C at a flow rate of 1.0 mL/minute. The major peak
of activity eluted at 1.0 M NaCl (Figure 1C). Pooled fractions, containing
250 to 500 g total proteins, were concentrated with a 50-kDa cutoff
centrifugal concentrator (Centriplus; Millipore, Bedford, MA) and freeze-
dried. Next, the sample was dissolved in 1.0% trifluoroacetic acid and
loaded onto a 1.0-mL C4 Symmetry 300 column (Waters, Milford, MA)
equilibrated with 0.1% trifluoroacetic acid (1.0 mL/minute) for the initial 30
minutes. Bound material was eluted at 1.0 mL/minute using a 40-minute
linear 0% to 50% acetonitrile gradient in 0.1% trifluoroacetic acid (Figure
1D). Collected fractions were freeze-dried, resuspended in 25 mM Mes/
NaOH (pH 7.0), and assessed for biologic activity and mass spectrometry
(MS) identification.
Mass spectrometry
Peptide mixtures from tryptic or CNBr digestions of biologically active
high-performance liquid chromatography (HPLC) fractions were desalted
and concentrated using C18 Zip Tips (Millipore) and analyzed by matrix-
assisted laser desorption/ionization time of flight mass spectrometry
(MALDI-ToF MS) (Voyager DE-sSTR; Applied Biosystems, Foster City,
CA) using a 337-nm wavelength laser for desorption and the reflectron
mode of analysis. Mass spectra of digested peptides were searched against
the FASTA database21 using the PROWL ProFound search engine22
(available at www.prowl.rockefeller.edu) using an unbiased all taxa
search. For amino acid sequencing, the peptide mixtures were also
analyzed by MS/MS (tandem mass spectrometry) using a Q-q-Tof
hybrid system (Q-Star XL; Applied Biosystems) equipped with a
nanospray ion source. In particular, the doubly charged ion of the
phosphopeptide (65-86) at m/z 1225.5287 was selected to sequence and
identify the Ser-77 phosphorylation site.
Three-dimensional gel and migration assays
MAE-cell aggregates were embedded in fibrin gel.17 Then, culture medium
containing the chromatographic fraction to be tested or murine rDrm (R&D
Systems, Minneapolis, MN) was added on the top of the gel in the presence
of 10 g/mL aprotinin to prevent the dissolution of the substrate. Formation
of radially growing cell sprouts was observed during the next 24 to 72
hours. Sprouts were photographed at  40 magnification (Olympus
[Melville, NY] IX51 inverted microscope equipped with a 4/0.10
numerical aperture [NA] objective and a Camedia C-4040 digital camera)
and quantified by computerized analysis of the digitalized images. Three-
dimensional gels of reconstituted rat tail tendon type I collagen fibrils
(Boehringer Mannheim, Monza, Italy) were prepared as described.17 Then,
BAE cells were seeded on the top of the collagen gel (80 000 cells/cm2) and
allowed to reach confluence. Cell cultures were then treated with fresh
medium containing rDrm plus 10% FCS. After 24 hours, cells were
photographed at  100 magnification (Olympus IX51 inverted microscope
equipped with a CAch 10/0.25 NA PhP objective), and endothelial cells
invading the gel, in a plane of focus beneath the cell monolayer surface,
were quantified by computerized analysis of the digitalized images. To
study migration, 50 000 MAE cells resuspended in DMEM plus 0.1%
heat-inactivated FCS were seeded in the upper compartment of a Boyden
chamber containing a gelatin-coated polycarbonate membrane filter (Nucleo-
pore, 8-m pores; Whatman, Mainstone, United Kingdom). rDrm and/or
BMP4 (R&D Systems) were dissolved in the same medium and placed in
the lower chamber. Then, cells were allowed to migrate for 4 hours at 37°C.
Migrated cells at the bottom surface of the filter were stained (Diff-Quick;
DADE Behring, Marburg, Germany) and counted at  250 magnification
(5 fields/sample in triplicate) using a Dialux 20 EB microscope (Leitz,
Wetzlar, Germany) equipped with an NPl 25/0.50 NA objective.
125I-Drm binding and cross-linking to endothelial cells
rDrm (5 g) was dissolved in 200 L PBS, transferred into iodogen-coated
tubes (Pierce, Rockford, IL), and incubated for 5 minutes at 4°C with 0.2
mCi [7.4 MBq] 125I (Amersham). The reaction products were separated on a
size-exclusion Sephadex-G10 column. For 125I-rDrm binding experiments,
SIE, MAE, and HUVE cells were plated in 24-well dishes at 70 000
cells/cm2. After 24 hours, cells were washed 3 times with ice-cold PBS and
incubated for 2 hours at 4°C in binding medium (serum-free medium
containing 0.15% gelatin, 20 mM HEPES, pH 7.5) with increasing
concentrations of 125I-Drm in the absence or in the presence of 100-fold
excess of unlabeled ligand. After a PBS wash, cells were washed twice with
2.0 M NaCl in 20 mM HEPES buffer (pH 7.5) to elute 125I-rDrm bound to
low-affinity sites. Next, 125I-rDrm bound to high-affinity sites was eluted
with 2.0 M NaCl in 20 mM sodium acetate (pH 4.0).23 Low-affinity and
high-affinity binding data were analyzed by Scatchard plot using Prism4
software (GraphPad Software, San Diego, CA).
For cross-linking experiment, confluent SIE and HUVE cells were
incubated for 10 minutes at room temperature in binding medium with 5.0
nM 125I-rDrm in the absence or presence of a 100-fold molar excess of
unlabeled rDrm or BMP4. Then, 1.0 mM bis[sulphosuccinamide]suberate
(Pierce) was added. The cross-linking reaction was allowed to proceed at
4°C for 2 hours. After a 2.0 M NaCl wash in 20 mM HEPES buffer (pH
7.5), cells were lysed and proteins were separated by 6% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions. Complexes were visualized by autoradiography of the gel.
In a second set of experiments, 107 confluent SIE cells were incubated
under the same experimental conditions with 5.0 nM unlabeled rDrm. After
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cross-linking, cells were lysed in lysis buffer [50 mM Tris-HCl buffer (pH
7.4) containing 150 mM NaCl, 1% Triton X-100, and protease and
phosphatase inhibitors (50g/mL pepstatin, 50g/mL leupeptin, 10g/mL
aprotinin, 1.0 mM Na3VO4; all from Sigma, St Louis, MO)], and the whole
sample (1.0 mg protein) was incubated with anti-Drm antibody (R&D
Systems). Immunocomplexes were precipitated by overnight incubation
at 4°C with Protein G-Sepharose beads and analyzed by Western
blotting under reducing conditions using the same anti-Drm antibody.
The lysate of cells in which rDrm incubation was omitted was used as a
negative control.
Intracellular signaling
Confluent SIE cells were made quiescent by a 20-hour starvation in 2%
FCS. After stimulation with rDrm (50 ng/mL), cells were lysed, and 20-g
aliquots were analyzed by 6% or 10% SDS-PAGE followed by Western
blotting with antibodies against pFAK, pPaxillin, pERK1/2, or Jak2 (Santa
Cruz Biotechnology, Santa Cruz, CA). For 2D-PAGE, samples were
solubilized in 8.0 M urea, 50 mM DTT, 4% CHAPS, 0.2% carrier
ampholytes (pH 3-10), 0.0002% bromophenol blue. Proteins were sepa-
rated on pH 3-10 NL IPG strips (Bio-Rad, Munich, Germany) according to
the manufacturer’s instructions. The second dimension was performed on
10% SDS-PAGE, and proteins were probed with anti-pTyr antibody (Santa
Cruz Biotechnology) in a Western blot. The same antibody was used to
decorate rDrm-stimulated, paraformaldehyde-fixed SIE cells.
Drm/gremlin transfection in COS cells
COS cells were transfected with the pMEXneo expression vector harboring
the rat Drm cDNA (pMEX-DRM) or with the empty vector (both provided
by D. G. Blair, National Cancer Institute [NCI]–Frederick, MD) to generate
stable transfectants (mock-COS cells and Drm-COS cells, respectively)
as described.24
Chicken embryo chorioallantoic membrane (CAM) assay
Gelatin sponges containing vehicle, 50 or 100 ng of rDrm or BMP4 or both
(n  10-20 eggs/group), were placed on the CAM of fertilized chicken eggs
at day 8 of incubation.25 In a parallel experiment, mock-COS cells and
Drm-COS cells were implanted via a gelatin sponge (18 000 cells/sponge)
on the top of the CAM at day 8 (n  20 eggs/group). At day 12, blood
vessels entering the sponge within the focal plane of the CAM were
counted at  50 magnification using a STEMI SR stereomicroscope
equipped with an objective f equal to 100 mm with adapter ring 47 50 70
(Carl Zeiss, Jena, Germany). When indicated, CAMs were processed
for light microscopy, and microvessel density was evaluated by a plani-
metric method.25
Drm/gremlin expression in tumor xenografts
Drm/gremlin transcripts were evaluated by reverse-transcription–polymer-
ase chain reaction (RT-PCR) analysis in human endometrial adenocarci-
noma HEC-1-B–derived xenografts26 (provided by R. Giavazzi, Mario
Negri Institute, Bergamo, Italy) using the following specie-specific primers:
murine Drm/gremlin [()CTCAGCACAATGACTCCGAGC; ()ATC-
CAAGTCGATGGATATGCAA], human Drm/gremlin [()GTATGAGC-
CGCACAGCCTACA; ()CTCGCTTCAGGTATTTGCGCT]. After PCR
reaction, 5-L aliquots were separated on a 1.5% agarose gel and
visualized by ethidium bromide staining. Also, paraffin-embedded tumor
samples were stained with anti-Drm/gremlin antibody as detailed in the
next paragraph.
Human lung tumor collection and immunohistochemistry
Ten samples of formalin-fixed and paraffin-embedded human lung cancers
(5 adenocarcinomas and 5 squamous-cell carcinomas) were obtained from
L. de Leval (Department of Pathology, Lie`ge University Hospital, Bel-
gium). Paraffin sections (5 m) were stained with a goat polyclonal
anti-Drm/gremlin antibody (R&D Systems) using the immunoperoxidase
ABC Vectastain Kit (Vector Laboratories, Burlingame, CA). Antigen
retrieval was performed by heating slides in a water-bath at 95°C for 40
minutes in 10 mM citrate buffer (pH 6.0). After blocking the endoge-
nous peroxidase activity with 0.3% H2O2 in methanol for 30 minutes,
slides were sequentially incubated with normal horse serum (1:20) for 30
minutes and with the anti-gremlin antibody (1:30) overnight at 4°C. Slides
were then incubated with biotinylated antigoat antibody (Vector Laborato-
ries) followed by the avidin-biotin-peroxidase complex. Hematoxylin-
counterstained sections were reviewed by 2 independent observers, and
immunostaining intensity in cancer cells and in endothelial cells was scored
as follows:  indicates negative; , weak staining; , strong staining.
Analysis of tissue sections was performed using a Zeiss Axiovert 200M
microscope equipped with an Achroplan 40/0.65 NA Ph2 or an Achroplan
20/0.45 NA objective.
Data representation
Data are expressed as mean SD. Statistical analyses were done using the
Student t test. The significance level was set at P values less than .01.
Results
Drm/gremlin purification
Preliminary observations had shown that FGF2-T-MAE cells
release an uncharacterized heparin-binding, heat-stable, protein-
aceous factor responsible for the capacity of their CM to induce
endothelial-cell sprouting in a fibrin gel.19 On this basis, we thought
to purify this protein sequentially using ammonium sulfate precipi-
tation, cation exchange chromatography, heparin-Sepharose affin-
ity chromatography, and reversed-phase HPLC (Figure 1). The
bioactivity of eluted fractions was monitored by stimulation of
MAE-cell sprouting in 3-dimensional fibrin gel (Figure 1A). Most
of the endothelial-cell sprouting–inducing activity present in the
serum-free CM of FGF2-T-MAE cells precipitates in 70% ammonium
sulfate and binds to an SP-Sepharose cation exchange column from
where it is recovered in the 0.8 to 0.9 M NaCl eluate (Figure 1B).
Subsequent fractionation by heparin-Sepharose chromatography
reveals a major peak of activity eluting at 1.0 M NaCl (Figure 1C).
Further purification by reversed-phase HPLC yields 2 biologically
active peaks (retention time of 24.6 and 26.7 minutes; Figure 1D).
Peptide mass fingerprinting analysis of both peaks by MALDI-
ToF mass spectrometry (MS) (Figure 1E) identifies the purified
endothelial-cell motogen as the murine Drm gene product. The
identification was confirmed by nano-ESI-MS/MS sequencing of
the peptides generated by tryptic and CNBr digestion of the
purified protein and by Western blotting of the bioactive HPLC
fractions (Figure 1D, inset).
Nano-ESI-MS/MS analysis also shows that purified Drm under-
goes posttranslational modifications, including maturation, glyco-
sylation, and phosphorylation, in keeping with previous observa-
tions in Drm-transfected COS cells.24 Indeed, purified Drm lacks
the leader sequence for secretion (amino acid sequence starting
from Lys-25) and carries one N-glycosylation at Asn-42 and one
phosphorylation at Ser-77 (Figure 1F). These posttranslational
modifications explain the presence of more Drm forms after HPLC
and Western blot analysis of the bioactive fractions (Figure 1D).
Drm/gremlin as an endothelial-cell motogen
To confirm the ability of Drm/gremlin to induce a motogenic
response in endothelial cells, increasing concentrations of recombi-
nant murine Drm (rDrm) were tested for the capacity to stimulate
the sprouting of MAE-cell aggregates in fibrin gel, the chemotactic
response of MAE cells in a Boyden chamber assay, and the
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invasion of type I collagen gel by BAE cells (Figure 2A). In all
the assays, rDrm stimulates endothelial-cell motility with a
maximal response at approximately 50 ng/mL. In keeping with
its motogenic activity, rDrm stimulates tyrosine phosphoryla-
tion of focal adhesion contacts (Figure 2A, inset) and phosphor-
ylation of focal adhesion kinase (FAK) (Figure 3B) in murine
dermal microvascular endothelial (SIE) cells. Taken together,
the data identify Drm/gremlin as a motility factor for endothelial
cells of different origin.
Drm/gremlin binding to endothelial cells
The capacity of rDrm to stimulate endothelial-cell motility and to
induce rapid intracellular phosphorylation events points to the
previously unrecognized possibility that Drm/gremlin may interact
directly with endothelial cells. Indeed, Scatchard plot analysis of
the binding data of 125I-rDrm to different endothelial cell types
(including SIE, MAE, and HUVE cells) revealed one class of
high-affinity binding sites with a Kd of 5.1 0.3 nM and a Bmax of
7000 1700 binding sites/cell (Figure 2B). As observed for other
heparin-binding angiogenic factors,27 125I-rDrm interacts also with
one class of low-affinity binding sites on the surface of the different
endothelial cell types (from 80 000 to 250 000 binding sites/cell)
with a Kd ranging between 30 nM and 300 nM. The capacity of free
heparin to fully prevent this binding (data not shown) is consistent
with the hypothesis that Drm/gremlin may engage a low-affinity
interaction with cell-surface heparan-sulfate proteoglycans.28
Cross-linking of rDrm to the cell surface followed by
immunoprecipitation with anti-Drm antibody shows that rDrm
binds to a cell-membrane protein, originating a Drm-immuno-
reactive protein complex with a molecular mass of approxi-
mately 250 kDa (Figure 2B, inset). Remarkably, 125I-rDrm/
receptor complex formation is prevented by a molar excess of
unlabeled rDrm but not of the Drm/gremlin ligand BMP4
Figure 1. Drm/gremlin purification from the CM of FGF2-T-
MAE cells. (A) FGF2-T-MAE-cell CM (bottom), but not MAE-
cell CM (top), stimulates sprouting of MAE-cell aggregates in
fibrin gel. This assay was used to follow the purification of
FGF2-T-MAE-cell CM by cation exchange (B) and heparin-
Sepharose (C) chromatography (horizontal bar, pooled bioac-
tive fractions; diagonal dashed lines, NaCl gradient), and by
reverse-phase HPLC (D). Bioactive HPLC peaks (*,**) were
probed with anti-Drm/gremlin antibodies in a Western blot
(D, inset) and identified by MALDI-ToF peptide mass fingerprint-
ing (peak * in panel E; peak **, not shown). (F) Amino acid
sequence of Drm/gremlin. Tryptic (underlined) or CNBr (italic)
digestion peptides were sequenced by nano-ESI-MS/MS.
N-glycosylation (N) and Ser-phosphorylation (S) sites are
highlighted.
Figure 2. rDrm interaction with endothelial cells. (A) rDrm induces MAE-cell
sprouting in fibrin gel (o), MAE-cell migration in a Boyden chamber (u), and BAE-cell
invasion in type I collagen gel (f) (data expressed as mean  SD); inset, tyrosine
phosphorylation of focal adhesion contacts (arrows) in SIE cells stimulated for 10
minutes with 100 ng/mL rDrm. Cell analysis was performed using a Zeiss Axiovert
200M microscope equipped with a Plan-Apochromat 63/1.4 NA oil objective.
(B) Binding of 125I-rDrm to SIE cells; inset, cross-linking of unlabeled rDrm to SIE
cells followed by immunoprecipitation and Western blotting with anti-Drm antibody.
(C) Cross-linking of 125I-rDrm to SIE cells with or without a 100-fold molar excess of
unlabeled rDrm or BMP4. 125I-rDrm complexes were visualized by autoradiography of
the SDS-PAGE gel.
Figure 3. rDrm-induced intracellular signaling. (A) Two-dimensional electrophore-
sis of control and rDrm-treated SIE-cell extracts decorated with anti–phospho-Tyr
antibody. (B) FAK, paxillin, and ERK1/2 phosphorylation in rDrm-treated SIE cells.
Anti-Jak2 antibody was used as loading control.
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(Figure 2C), indicating that BMP interaction does not hamper
the receptor-binding capacity of rDrm.
In keeping with the presence of a cell-surface receptor, rDrm
causes the rapid appearance of a composite tyrosine phosphory-
lation pattern in endothelial SIE cells (Figure 3A). As antici-
pated for a cell-motility factor, paxillin, FAK, and mitogen-
activated protein kinase ERK1/2 are targets of rDrm-activated
signaling (Figure 3B). Taken together, the data demonstrate for
the first time the capacity of Drm/gremlin to exert a direct,
productive interaction with endothelial cells by engaging cell-
surface receptor(s) whose identification will require further
investigation.
Angiogenic activity of Drm/gremlin
To assess the effect of Drm/gremlin on blood vessel formation in
vivo, rDrm (100 ng/egg) was delivered on the top of the chick
embryo CAM at day 8 of development via a gelatin sponge
implant.25A potent angiogenic response was observed around the
rDrm implants when compared with vehicle-treated embryos
(Figure 4A-B), the number of macroscopic blood vessels converg-
ing toward the gelatin sponge being significantly higher (P  .01)
in rDrm than in vehicle implants (Table 1). Histologic morphomet-
ric analysis of microvessel density within the gelatin implants
confirmed the proangiogenic activity of rDrm (Figure 4C-D;
Table 1). To substantiate these observations, we transfected COS
cells with an expression vector harboring the rat Drm cDNA.
Transfectants produce and release significant amounts of the
recombinant protein (Figure S1, available on the Blood website;
see the Supplemental Figure link at the top of the online article).
Accordingly, a potent angiogenic response was observed in chick
embryo CAMs implanted with Drm-transfectants when compared
with mock-transfected cells (Figure S1; Table 1).
Effect of BMP4 on the angiogenic activity of Drm/gremlin
Our data indicate that rDrm binds to endothelial cells in a
BMP-independent manner (see Figure 2C). However, previous
observations had shown that BMPs are endowed with angiogenic
activity.29,30 Accordingly, the Drm/gremlin ligand BMP4 is a
chemoattractant for MAE cells and causes neovascularization in
the chick CAM (Figure 5A-B). On this basis, we investigated the
effect of BMP4 on the angiogenic activity of rDrm in vitro and in
vivo. As shown in Figure 5A, stimulation of MAE cells with a
suboptimal concentration of rDrm (5.0 ng/mL) in the presence of
increasing concentrations of BMP4 resulted in an increased
chemotactic response. Similarly, the simultaneous delivery of rDrm
and BMP4 on the chick CAM triggered a more potent angio-
genic response when compared with that induced by rDrm alone
(Figure 5B).Taken together, these observations support the hypoth-
esis that Drm/gremlin exerts its angiogenic activity on endothelium
via a BMP-independent mechanism of action.
Drm/gremlin expression in tumor vasculature
Recent observations have shown that Drm/gremlin is up-regulated
in human cancers.31 To gain insights about a possible role of
Drm/gremlin in tumor vascularization, we performed immunohisto-
chemical analysis of experimental and human tumors. Highly
vascularized tumor xenografts generated by subcutaneous injection
in nude mice of human adenocarcinoma HEC-1-B–derived cells26
showed a strong Drm immunoractivity in the tumor stroma,
whereas tumor parenchyma was negative (Figure 6A-B). RT-PCR
analysis of total RNA from these lesions using specie-specific
primers confirmed the murine stromal origin of Drm/gremlin and
the lack of human Drm/gremlin transcripts (Figure 6).
Figure 4. Proangiogenic activity of rDrm. Chick embryo CAM implants (asterisk
indicates gelatin sponge) were loaded with vehicle (A) or 100 ng rDrm (B). Note the
numerous blood vessels converging versus the rDrm implant. (C-D) Toluidine blue
staining of histologic sections of CAM treated with vehicle (C) or 100 ng rDrm (D).
Numerous capillaries filled with nucleated avian erythrocytes are present among the
trabeculae of the rDrm-treated sponge (arrows in panel D).
Figure 5. Effect of BMP4 on the angiogenic activity of Drm/gremlin. (A) The
chemotactic activity of a suboptimal concentration of rDrm (5.0 ng/mL) was tested on
MAE cells in a Boyden chamber assay in the presence of increasing concentrations
of BMP4 (F); in parallel, the chemotactic activity of BMP4 alone was tested on the
same cells (E). (B) Chick embryo CAM implants were loaded with vehicle, BMP4,
rDrm, or rDrm plus BMP4 (both molecules were tested alone or in combination at
50 or 100 ng/implant). After 4 days, blood vessels converging versus the implant were
counted. Data are expressed as mean  SD.
Table 1. Chick embryo CAM assay: macroscopic and microscopic
assessment of Drm-induced neovascularization
Treatment n
Blood vessels,*
mean SD
Intersection points,†
mean SD
Microvessel
density,† %
Vehicle 10 6  3 0 0.0
rDrm 20 27  4‡ 23  3 16.0
Mock-COS cells 20 10  3 5  2 3.5
Drm-COS cells 20 28  3‡ 24  2 16.6
Gelatin sponges containing vehicle, 100 ng rDrm, mock-transfected or Drm-
transfected COS cells (18 000 cells per sponge) were implanted on top of chick
embryo CAMs at day 8.
*The angiogenic response was assessed macroscopically at day 12 by counting
the number of blood vessels entering the sponge.
†The angiogenic response was assessed histologically by a planimetric method
of “point counting” as described.24
‡P  .001 versus vehicle and Mock-COS cells.
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The cancer profiling DNA microarray database Oncomine 2.0
contains publicly available gene expression sets generated from
approximately 60 tumor panels covering 20 different human
malignancies.32 Database mining reveals that Drm is significantly
overexpressed in lung adenocarcinoma and squamous-cell carci-
noma specimens when compared with normal lung (P  .001).
Accordingly, immunostaining of 10 lung cancer samples (Table 2)
demonstrated that endothelial cells of vessels infiltrating or adja-
cent to tumor cells strongly express Drm/gremlin (Figure 7A-C).
Cancer cells lacked Drm/gremlin expression in 7 cases and showed
a weak cytoplasmic immunostaining in the remaining 3 cases
(Table 2). In all cases, endothelium of the nonneoplastic lung tissue
adjacent to tumor lesions showed no or very weak immunoreactiv-
ity (Figure 7D).
Discussion
Our results show for the first time the capacity of Drm/gremlin to
induce a motile and invasive phenotype in endothelial cells in vitro
and a potent angiogenic response in vivo. This reflects the
previously unrecognized ability of Drm/gremlin to interact with
high-affinity binding sites on endothelial cells in a BMP-
independent manner and to trigger a complex intracellular signal-
ing cascade.
Drm/gremlin exerts a BMP antagonist activity by binding
BMP2, BMP4, and BMP7.3 Previous observations had shown
that BMP2 and BMP4 are endowed with angiogenic activity.29,30
Here, we have confirmed these observations by showing that
BMP4 exerts a significant angiogenic response in the chick
embryo CAM. However, BMP4 does not hamper Drm/gremlin
interaction with endothelial-cell receptors, and the simultaneous
exposure of endothelium to both rDrm and BMP4 results in a
potentiated chemotactic and angiogenic response in vitro and in
vivo, respectively. Our observations support the hypothesis that
Drm/gremlin exerts its angiogenic activity on endothelium via a
BMP-independent mechanism of action. Further experiments
are required to fully dissect the complex interplay among
Drm/gremlin, BMPs, and their cognate receptors.
Drm/gremlin is overexpressed in human cancers.31 We have
found that human tumor xenografts in nude mice express Drm.
Drm transcripts are synthesized by cells of the host within the
tumor, as shown by RT-PCR analysis using specific murine
primers, and Drm/gremlin protein accumulates in the stroma of
the tumor. Also, we have observed a strong Drm/gremlin
immunoreactivity in endothelial cells of human lung tumor
samples, absent in adjacent nonneoplastic lung tissue. Recombi-
nant FGF2 up-regulates Drm expression in endothelial cells of
different origin (M.P., unpublished observations, October 2006).
This is in keeping with the capacity of FGF2, as well as of
BMP2 and platelet-derived growth factor, to induce Drm/
gremlin production in rat osteoblasts33 and with the role of
Drm/gremlin in the sonic hedgehog/FGF feedback loop in
vertebrate limb bud.34 The possibility that Drm/gremlin pro-
duced by tumor cells and/or by growth factor–activated endothe-
lium may contribute to neovascularization in experimental and
human neoplasms deserves further investigation.
Secreted Drm/gremlin binds to various BMPs.3 Also, Drm/
gremlin has been shown to bind Slit proteins and to act as
inhibitor of monocyte chemotaxis.8 Moreover, a possible intra-
cellular, BMP-independent mechanism of action has been
hypothesized for this protein.6 Our observations point out the
Figure 6. Drm/gremlin expression in tumor xenografts. (A) Drm/gremlin immuno-
staining of tumor xenografts originated in nude mice by subcutaneous injection of
human endometrial adenocarcinoma HEC-1-B–derived cells. Note the Drm/gremlin
immunoreactivity in tumor stroma, absent in tumor parenchyma. (B) Negative
control in which the primary antibody was omitted. Original magnification,  200.
(C) RT-PCR analysis of 4 tumor xenografts (T) using murine and human specific
Drm/gremlin primers.
Table 2. Immunohistochemical analysis of Drm/gremlin expression
in human lung tumors
Lung tumors
No. of tumors with the indicated Drm/gremlin
immunostaining intensity
Cancer-cell
immunostaining
Endothelial-cell
immunostaining
     
Adenocarcinomas 4 1 0 0 0 5
Squamous-cell carcinomas 3 2 0 0 1 4
Paraffin-embedded human lung cancer specimens (for each type listed in the
table, n  5) were analyzed for Drm/gremlin expression by immunostaining. Cancer
cells and endothelial cells of each specimen were scored for Drm/gremlin immunore-
activity on an arbitrary scale:  indicates negative; , weak staining; , strong
staining.
Figure 7. Drm/gremlin immunohistochemistry in human lung cancers. Endothe-
lial cells of tumor vessels (arrows) show a strong Drm/gremlin immunoreactivity in
human lung squamous-cell carcinoma (A) and adenocarcinoma (B-C). Squamous
tumor cells are weakly immunoreactive (A). No or very weak immunoreactivity is
detected in nonneoplastic lung tissue adjacent to the tumor (D). Original magnifica-
tion, 200 (A,D); 400 (B,C).
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previously unrecognized capacity of Drm/gremlin to interact
with signaling receptor(s) in endothelial cells with possible
implications in angiogenesis. Thus, Drm/gremlin may exert
multiple functions by interacting with different partners. The
ability of Drm/gremlin to act directly on target endothelial cells
via a receptor-mediated mechanism of action sheds new light on
its putative role in embryogenesis and human diseases, includ-
ing cancer.
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